Literature DB >> 16735097

Vasculopathy in two cases of NF1-related congenital pseudarthrosis.

Tommi Kuorilehto1, Pentti Kinnunen, Marja Nissinen, Maria Alanne, Hannu-Ville Leskelä, Petri Lehenkari, Juha Peltonen.   

Abstract

Neurofibromatosis type 1 (NF1) is a common dominantly inherited disease. More than half of NF1 patients suffer from skeletal manifestations, of which congenital pseudarthrosis of tibia (CPT) is one of the most incapacitating lesions. Two NF1 patients with CPT were operated, and the resected tissues were analyzed using immunohistochemistry and/or in situ hybridization for NF1 protein and mRNA, p-p44/42 MAPK, and S100 protein. Both patients displayed thick-walled arteries and veins with a small lumen within the fibrotic tissue in the vicinity of pseudarthrosis. Endothelial cells were highly positive for p-p44/42 MAPK. A subpopulation of cells surrounding the blood vessels was S100 protein-positive. However, the exact identity of the S100-positive cells remains to be elucidated. Neurofibromin mRNA and protein labeling was detected in both cell types. In conclusion, decreased NF1 function as a RAS-GAP in the endothelium may contribute to vascular thickening in CPT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735097     DOI: 10.1016/j.prp.2006.03.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.

Authors:  Wei Zhang; Steven D Rhodes; Liming Zhao; Yongzheng He; Yingze Zhang; Yong Shen; Dalong Yang; Xiaohua Wu; Xiaohong Li; Xianlin Yang; Su-Jung Park; Shi Chen; Charles Turner; Feng-Chun Yang
Journal:  Bone       Date:  2011-03-23       Impact factor: 4.398

2.  Novel method for the treatment of congenital pseudarthrosis of the tibia using the gastrocnemius flap: A preliminary study.

Authors:  Wenquan Cai; Yuxi Su; Guoxin Nan
Journal:  J Child Orthop       Date:  2022-06-30       Impact factor: 1.917

3.  Combination of the Ilizarov Method and Intramedullary Fixation for the Treatment of Congenital Pseudarthrosis of the Tibia in Children: A Retrospective Observational Study.

Authors:  Ainizier Yalikun; Maimaiaili Yushan; Yimurang Hamiti; Cheng Lu; Aihemaitijiang Yusufu
Journal:  Front Surg       Date:  2022-05-17

4.  Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.

Authors:  Richa Sharma; Xiaohua Wu; Steven D Rhodes; Shi Chen; Yongzheng He; Jin Yuan; Jiliang Li; Xianlin Yang; Xiaohong Li; Li Jiang; Edward T Kim; David A Stevenson; David Viskochil; Mingjiang Xu; Feng-Chun Yang
Journal:  Hum Mol Genet       Date:  2013-07-17       Impact factor: 6.150

5.  Combined technique with hydroxyapatite coated intramedullary nails in treatment of anterolateral bowing of congenital pseudarthrosis of tibia.

Authors:  Dmitry Popkov; Arnold Popkov; Siniša Dučić; Mikan Lazović; Pierre Lascombes
Journal:  J Orthop       Date:  2019-11-12

6.  The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1.

Authors:  Xiaohua Wu; Shi Chen; Yongzheng He; Steven D Rhodes; Khalid S Mohammad; Xiaohong Li; Xianlin Yang; Li Jiang; Grzegorz Nalepa; Paige Snider; Alexander G Robling; D Wade Clapp; Simon J Conway; Theresa A Guise; Feng-Chun Yang
Journal:  PLoS One       Date:  2011-09-29       Impact factor: 3.240

7.  Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin.

Authors:  Mateusz Kolanczyk; Jirko Kühnisch; Nadine Kossler; Monika Osswald; Sabine Stumpp; Boris Thurisch; Uwe Kornak; Stefan Mundlos
Journal:  BMC Med       Date:  2008-07-31       Impact factor: 8.775

Review 8.  Current Aspects on the Pathophysiology of Bone Metabolic Defects during Progression of Scoliosis in Neurofibromatosis Type 1.

Authors:  Angelos Kaspiris; Olga D Savvidou; Elias S Vasiliadis; Argyris C Hadjimichael; Dimitra Melissaridou; Stella Iliopoulou-Kosmadaki; Ilias D Iliopoulos; Evangelia Papadimitriou; Efstathios Chronopoulos
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.